Opinion

Video

Treatment Selection in Second Line R/R DLBCL

Author(s):

Sonali Smith, MD,Krish Patel, MD

Expert perspectives on treatment selection for patients with R/R DLBCL receiving second line therapy.

Related Videos
Ashkan Emadi, MD, PhD
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.
Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma
Related Content
OncLive’s December Roundup of Key FDA Approvals in Oncology
December 30th 2024

OncLive’s December Roundup of Key FDA Approvals in Oncology

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

Joseph A. Sparano, MD, FACP
December 23rd 2024

Tailor-Made for a Lifelong Pursuit of Precision in Cancer Care

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Acute Myeloid Leukemia | Image Credit: © Tatiana Shepeleva – stock.adobe.com
December 20th 2024

Uproleselan Plus Chemo Fails to Improve OS in R/R AML in China

CP-CML | Image Credit: © สุพัฒตรา แสนพลี – stock.adobe.com
December 19th 2024

Olverembatinib Demonstrates Efficacy and Safety in Heavily Pretreated CP-CML